Version 1
: Received: 19 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (19:10:09 CET)
How to cite:
Chitnis, A.V.; Rathi, A. In-vitro Virucidal Activity of Commercial Enzyme Preparations against SARS-CoV-2 Virus. Preprints2020, 2020120543. https://doi.org/10.20944/preprints202012.0543.v1
Chitnis, A.V.; Rathi, A. In-vitro Virucidal Activity of Commercial Enzyme Preparations against SARS-CoV-2 Virus. Preprints 2020, 2020120543. https://doi.org/10.20944/preprints202012.0543.v1
Chitnis, A.V.; Rathi, A. In-vitro Virucidal Activity of Commercial Enzyme Preparations against SARS-CoV-2 Virus. Preprints2020, 2020120543. https://doi.org/10.20944/preprints202012.0543.v1
APA Style
Chitnis, A.V., & Rathi, A. (2020). In-vitro Virucidal Activity of Commercial Enzyme Preparations against SARS-CoV-2 Virus. Preprints. https://doi.org/10.20944/preprints202012.0543.v1
Chicago/Turabian Style
Chitnis, A.V. and Abhijit Rathi. 2020 "In-vitro Virucidal Activity of Commercial Enzyme Preparations against SARS-CoV-2 Virus" Preprints. https://doi.org/10.20944/preprints202012.0543.v1
Abstract
Prevention practices have been extensively used to contain the spread of the SARS-CoV-2 virus. These include social distancing, wearing masks, disinfection of hands, and sanitization of contact surfaces. However, the excessive usage of chemical disinfectants pose long term adverse effects to human health and the environment. Development of effective and environmentally friendly biocides, or virucidal agents, will help mitigate the ill effects of chemical disinfectants. Enzymes are potential candidates for the preparation of biocides against bacteria and viruses. Exploration of the virucidal activity of commercial enzymes, will highlight prospective, readily available sources for research on enzyme based biocides. In this study, the virucidal effect of some com-mercial enzyme preparations has been investigated against the SARS-CoV-2 virus. Vida Defense (2000 µg/ml), Excellacor (1500 µg/ml), and SEBkinase (3000 µg/ml) reduced SARS-CoV-2 viral ti-ters by ≥1 log CCID50 (≥90%). ImmunoSEB (6000µg/ml) and Peptizyme SP (500µg/ml) reduced the SARS-CoV-2 viral titers by 0.8 log CCID50 (84.2%). The study indicates that enzyme prepara-tions offer the potential to be explored further for an anti-viral biocide against SARS‐CoV‐2 for reducing the risk of COVID‐19 transmission. However, further studies are mandated to improve efficacy and establish safety.
Keywords
SARS-CoV-2; enzymes; virucidal; biocide
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
